Oregovomab

Oregovomab (Alt-2 monoclonal antibody) is a murine mAb targeting CA125. Oregovomab induces cytotoxic immune response against CA125 expressing tumor cells[1][2].

Product Specifications

CAS Number

[213327-37-8]

Product Name Alternative

Alt-2 monoclonal antibody; MAB-B43.13; Oregovamab

UNSPSC

12352203

Target

Transmembrane Glycoprotein

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

99.66

Solubility

10 mM in DMSO

Smiles

[Oregovomab]

Molecular Weight

(146.72 kDa)

References & Citations

[1]Pietragalla A, et al. Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. Expert Opin Investig Drugs. 2021 Feb;30 (2) :103-110. |[2]Sparholt MH, et al. Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic? APMIS. 2013 Jan;121 (1) :38-44.